HLA class II histocompatibility antigen DP (HLA-DP)

HLA class II histocompatibility antigen DP (HLA-DP) is a heterodimeric cell-surface receptor belonging to the major histocompatibility complex (MHC) class II family, composed of an alpha (DPA1) and a beta (DPB1) chain (UniProt: P20036, P04440). It is primarily expressed on professional antigen-presenting cells such as B cells, macrophages, and dendritic cells, where it presents exogenous peptide antigens to CD4+ T-helper cells to initiate adaptive immune responses (StatPearls: MHC Class II). HLA-DP plays a significant role in disease susceptibility; for instance, specific HLA-DPB1 alleles are linked to chronic Hepatitis B infection and sarcoidosis (PubMed: 25188341). In clinical transplantation, HLA-DPB1 mismatches between donor and recipient are major drivers of graft-versus-host disease (GVHD) and transplant rejection (PubMed: 26130761). While traditional immunosuppressants like Tacrolimus and Cyclosporine indirectly modulate HLA-DP-mediated T-cell activation, novel therapeutic strategies include monoclonal antibodies designed to block specific DP alleles or the DP-T-cell receptor interface (PubMed: 31213547). Understanding the polymorphic nature of HLA-DP is crucial for risk stratification in immunotherapy and improving the success rates of hematopoietic stem cell transplants.

Other names

HLA-DPB1HLA-DPA1MHC class II DPDP antigenHuman leukocyte antigen DPMajor histocompatibility complex class II DP

Modulation of T-cell activation by inhibiting antigen presentation or downstream signaling pathways.